Literature DB >> 22898389

Clinical epidemiology of 960 patients with invasive aspergillosis from the PATH Alliance registry.

William J Steinbach1, Kieren A Marr, Elias J Anaissie, Nkechi Azie, Shun-Ping Quan, Herwig-Ulf Meier-Kriesche, Senu Apewokin, David L Horn.   

Abstract

OBJECTIVES: The study investigated the epidemiology and outcome of invasive aspergillosis (IA), an important cause of morbidity and mortality in immunocompromised patients.
METHODS: Cases of proven/probable IA from the Prospective Antifungal Therapy Alliance (PATH Alliance(®)) registry - a prospective surveillance network comprising 25 centers in the United States and Canada that collected data on invasive fungal infections from 2004 to 2008 - were analyzed with respect to clinical outcome.
RESULTS: Nine hundred and sixty patients with IA were enrolled, the most frequent underlying disease being hematologic malignancy (n=464 [48.3%]). Two hundred and eighty patients (29.2%) received solid organ transplant; 268 patients (27.9%) underwent hematopoietic stem cell transplantation. Identified isolates included Aspergillus fumigatus (72.6%), Aspergillus flavus (9.9%), Aspergillus niger (8.7%) and Aspergillus terreus (4.3%). The lung was most frequently affected. Following diagnosis, 47% patients received monotherapy - voriconazole (70%), an amphotericin B formulation (13.8%), or an echinocandin (10.5%) - while 279 patients (29%) received combination therapy. Twelve-week overall survival was 64.4%.
CONCLUSIONS: In this series of patients with IA, the lung was the predominant focus of infection, A. fumigatus was the major species isolated, and overall survival appeared slightly improved compared with previous reports.
Copyright © 2012 The British Infection Association. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22898389     DOI: 10.1016/j.jinf.2012.08.003

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  104 in total

Review 1.  [Resistant fungi].

Authors:  M J G T Vehreschild; O A Cornely
Journal:  Internist (Berl)       Date:  2015-11       Impact factor: 0.743

2.  MiR-146a Negatively Regulates Aspergillus fumigatus-Induced TNF-α and IL-6 Secretion in THP-1 Macrophages.

Authors:  Jianbo Tong; Zhimin Duan; Rong Zeng; Leilei Du; Song Xu; Liwei Wang; Yuzhen Liu; Qing Chen; Xu Chen; Min Li
Journal:  Mycopathologia       Date:  2021-06-04       Impact factor: 2.574

Review 3.  Alarmin(g) the innate immune system to invasive fungal infections.

Authors:  Alayna K Caffrey; Joshua J Obar
Journal:  Curr Opin Microbiol       Date:  2016-06-27       Impact factor: 7.934

Review 4.  Emerging threat of triazole-resistant Aspergillus fumigatus.

Authors:  Jeffrey M Rybak; Jarrod R Fortwendel; P David Rogers
Journal:  J Antimicrob Chemother       Date:  2019-04-01       Impact factor: 5.790

Review 5.  Immune responses to invasive aspergillosis: new understanding and therapeutic opportunities.

Authors:  Tobias M Hohl
Journal:  Curr Opin Infect Dis       Date:  2017-08       Impact factor: 4.915

6.  The Prospective Antifungal Therapy Alliance(®) registry: A two-centre Canadian experience.

Authors:  Shariq Haider; Coleman Rotstein; David Horn; Michel Laverdiere; Nkechi Azie
Journal:  Can J Infect Dis Med Microbiol       Date:  2014       Impact factor: 2.471

7.  Administration of Zinc Chelators Improves Survival of Mice Infected with Aspergillus fumigatus both in Monotherapy and in Combination with Caspofungin.

Authors:  Paris Laskaris; Ahmad Atrouni; José Antonio Calera; Christophe d'Enfert; Hélène Munier-Lehmann; Jean-Marc Cavaillon; Jean-Paul Latgé; Oumaïma Ibrahim-Granet
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

8.  In vitro combination of voriconazole and miltefosine against clinically relevant molds.

Authors:  S Imbert; M Palous; I Meyer; E Dannaoui; D Mazier; A Datry; A Fekkar
Journal:  Antimicrob Agents Chemother       Date:  2014-09-08       Impact factor: 5.191

9.  A 76-year-old man with a right lung adenocarcinoma and invasive Aspergillosis.

Authors:  Vitorino Modesto Dos Santos; Marcos Correa da Trindade; Diogo Wagner da Silva de Souza; Ana Isabel Costa de Menezes; Patricia Midori Oguma; Afonso Lucas Oliveira Nascimento
Journal:  Mycopathologia       Date:  2013-04-25       Impact factor: 2.574

Review 10.  Impact of multidrug-resistant organisms on patients considered for lung transplantation.

Authors:  Shmuel Shoham; Pali D Shah
Journal:  Infect Dis Clin North Am       Date:  2013-04-17       Impact factor: 5.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.